期刊
STEM CELL REPORTS
卷 7, 期 4, 页码 619-634出版社
CELL PRESS
DOI: 10.1016/j.stemcr.2016.08.011
关键词
-
资金
- Ministry of Education, Culture, Sports, Science and Technology of Japan [25293357]
- Charitable Trust Fund for Ophthalmic Research in Commemoration of Santen Pharmaceutical's Founder
- MEXT
- Grants-in-Aid for Scientific Research [25293357] Funding Source: KAKEN
Allografts of retinal pigment epithelial (RPE) cells have been considered for the treatment of ocular diseases. We recently started the transplantation of induced pluripotent stem cell (iPSC)-derived RPE cells for patients with age-related macular degeneration (autogenic grafts). However, there are at least two problems with this approach: (1) high cost, and (2) uselessness for acute patients. To resolve these issues, we established RPE cells from induced iPSCs in HLA homozygote donors. In vitro, human T cells directly recognized allogeneic iPSC-derived RPE cells that expressed HLA class I/II antigens. However, these T cells failed to respond to HLA-A, -B, and -DRB1-matched iPSC-derived RPE cells from HLA homozygous donors. Because of the lack of T cell response to iPSC-derived RPE cells from HLA homozygous donors, we can use these allogeneic iPSC-derived RPE cells in future clinical trials if the recipient and donor are HLA matched.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据